Andrew P. Andonopoulos

Experience with rituximab in scleroderma: results from a 1-year, proof-of-principle study

Dimitrios Daoussis, Stamatis‐Nick C. Liossis, Athanassios C. Tsamandas et al. · Lara D. Veeken · 2009 · 392 citations · Full text

Evidence that Dkk‐1 is dysfunctional in ankylosing spondylitis

Dimitrios Daoussis, Stamatis‐Nick C. Liossis, Elena E. Solomou et al. · Arthritis & Rheumatism · 2009 · 233 citations

A multicenter, open-label, comparative study of B-cell depletion therapy with Rituximab for systemic sclerosis-associated interstitial lung disease

Dimitrios Daoussis, Ioannis Antonopoulos, Theodora E. Markatseli et al. · Seminars in Arthritis and Rheumatism · 2016 · 209 citations

Autoimmune Disease, B-cell Depletion Therapy, Immunology +6

Effect of long-term treatment with rituximab on pulmonary function and skin fibrosis in patients with diffuse systemic sclerosis.

Dimitrios Daoussis, Stamatis‐Nick C. Liossis, Athanassios C. Tsamandas et al. · PubMed · 2012 · 184 citations

Mycophenolate mofetil as first-line treatment improves clinically evident early scleroderma lung disease

Stamatis‐Nick C. Liossis, Andreas Bounas, Andrew P. Andonopoulos · Lara D. Veeken · 2006 · 181 citations · Full text